The RS Biotherapeutics team is excited to attend CannMed23!

• 举报此文章

RS BioTherapeutics, Inc.

RS BioTherapeutics, Inc.

The Pulmonary Inflammation Company

发布日期: 2023年5月8日

+ 关注

Our team is excited to attend CannMed23! Looking forward to a great conference and sharing more about our first investigational compound (RSBT-001) in development as an alternative to corticosteroids in the treatment of pulmonary inflammation. Stop by our booth and let’s connect!

#CannMed23 #RSBioTherapeutics #pulmonaryinflammation #COPD

要查看或添加评论，请登录

RS BioTherapeutics, Inc.的更多文章

• 2025年1月21日

  RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue

  First-in-class, steroid-free compound reduced inflammatory and fibrotic biomarkers in human lung tissue furthering…

  49

  8 条评论
• 2024年7月8日

  RS BioTherapeutics Announces Research Collaboration with University of Colorado School of Medicine

  Collaboration to focus on RS BioTherapeutics’ first-in-class, steroid-free, therapeutic platform in the treatment of…

  46

  1 条评论
• 2024年4月30日

  RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine

  April 30, 2024 10:00 ET | Source: RS BioTherapeutics CUMBERLAND, Md., April 30, 2024 (GLOBE NEWSWIRE) -- RS…

  25
• 2024年4月25日

  RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board

  Ms. Wright-Mitchell to serve as fractional General Counsel and Compliance Advisor April 25, 2024 10:00 ET | Source: RS…

  35
• 2024年3月18日

  RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit

  CUMBERLAND, Md., March 18, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing…

  20
• 2024年2月21日

  RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance

  RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance on Development of First-in-Class Agent…

  39

  1 条评论
• 2023年10月31日

  RS BioTherapeutics Promotes Michelle L. Shuffett, MD to Chief Medical Officer

  CUMBERLAND, Md., Oct.

  20

  4 条评论
• 2023年8月29日

  New Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis

  RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention…

  25

  2 条评论
• 2023年6月5日

  RS BioTherapeutics Appoints Michelle L. Shuffett, MD as SVP of Medical and Scientific Affairs

  CUMBERLAND, Md., June 05, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic…

  30

  5 条评论
• 2023年5月15日

  RS BioTherapeutics Joins BioNTX Bioscience and Healthcare Innovation Trade Organization

  CUMBERLAND, Md., May 15, 2023 (GLOBE NEWSWIRE) — RS BioTherapeutics, whose mission is to harness the therapeutic power…

  25

  3 条评论

Show more

See all articles